Prime Medicine, Inc. (PRME)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.70-0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PRME
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 541.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PRME — earnings in line
Dated 2026-08-06
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Good clinical data could help with the BLA filing. It may also boost investor trust.
Supportive ifEarly clinical data from PM359 shows good results in patients with CGD.
Worry ifClinical data from PM359 shows no real improvement or bad results.
Why it matters: The earnings report will clarify the impact of the recent earnings miss on future performance.
Watch forEarnings report shows revenue growth or improved guidance after the earnings miss.
Also watch forEarnings report confirms further revenue decline or weak guidance.
Why it matters: The new CFO may change financial strategy and daily operations.
Supportive ifThe new CFO shares a plan that makes the financial outlook better.
Worry ifNo significant changes or strategies announced by the new CFO.
Why it matters: Updates on PM647 could show if the partnership is working. This may lead to more money.
Supportive ifLook for news about good trial results or new partnerships for PM647.
Worry ifWatch for news about delays or problems in PM647 development.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$330 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $878 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,952 loss on $10,000 · 59.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash runway are important. They help us see if the company can fund operations into 2027.
Worry ifCash and investments are enough to fund operations through 2027.
Less concerning ifAnnouncement of a cash shortfall or need for more funding before 2027.
Why it matters: Submitting the IND for PM647 would show progress in treating Alpha-1 Antitrypsin Deficiency. This is a key step toward clinical trials.
Supportive ifThe company submits the IND and/or CTA for PM647 in AATD as planned in Q3 2026.
Worry ifThe company delays the IND submission for PM647 beyond Q3 2026.
Why it matters: Initial data from PM577a could support the company's method for treating Wilson disease. Good results would increase trust in the pipeline.
Supportive ifThe company shares early clinical data from the Phase 1/2 trial of PM577a for Wilson disease.
Worry ifThe company fails to release initial clinical data from PM577a in 2027.
Why it matters: Updates on PM647 may show progress in an important program for Prime Medicine.
Supportive ifAnnouncement of IND filing for PM647 in AATD by mid-2026.
Worry ifNo announcement of IND filing for PM647 by mid-2026.
Why it matters: Filing the IND would mark a key step in bringing PM577 closer to clinical trials.
Supportive ifAn official announcement of the IND submission for PM577 by the end of H1 2026.
Worry ifNo announcement of the IND submission by the end of H1 2026.
Why it matters: A BLA submission for PM359 would be an important step in regulation. It shows progress in treating Chronic Granulomatous Disease.
Supportive ifThe company submits the BLA for PM359 as planned in the first half of 2027.
Worry ifThe company delays the BLA submission for PM359 beyond H1 2027.